NCT02694263 - Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 13, 2018

Study Completion Date

September 13, 2018

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Canagliflozin

Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.

DRUG

Repaglinide

Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.

DRUG

Pioglitazone

Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.

DRUG

Gliclazide

Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.

DRUG

Glimepiride

Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.

Trial Locations (2)

LE5 4PW

University Hospitals of Leicester NHS Trust, Leicester

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

All Listed Sponsors

collaborator

University Hospital Birmingham

OTHER

lead

University of Leicester

OTHER